睿知中国疾病研究地图
候选清单0

正在招募再生障碍性贫血早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia

ClinicalTrials.gov 上登记的一项再生障碍性贫血开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06633328,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. Less than 100 days after allogeneic hematopoietic stem cell transplantation;

    排除标准第 5 条

    Received anti-cancer chemotherapy or other drug treatment within 2 weeks prior to screening;

    排除标准第 8 条

  2. ECOG performance status 0 to 1;

    入选标准第 8 条

  3. creatinine clearance > 60ml/min; without liver invasion, serum total bilirubin ≤ 1.5 times the upper limit of normal, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were both ≤ 3 times the upper limit of the normal range. If there is liver invasion, serum erythrambirubin ≤ 3 times the upper limit of normal, and serum ALT and AST are both ≤ 5 times the upper limit of the normal range;

    入选标准第 4 条

  4. Patients with HIV infection,Active infection of hepatitis B virus or hepatitis C virus,Uncured active infection;

    排除标准第 6 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06633328,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Chinese expert consensus on the diagnosis and treatment of aplastic anemia(2017), Diagnosis of severe aplastic anemia ,1. The degree of bone marrow cell proliferation < 25%, or 25%-50% but residual hematopoietic cells < 30%;2. With pancytopenia (at least two of the following peripheral blood parameters) : (1) absolute neutrophil <0.5×10\^9/L; (2) Platelet count< 20×10\^9/L; (3) The absolute value of reticulocytes <20×109/L;
  2. Suitable donors (relatives) with allogeneic HSCT indications and at least haploid allogeneic transplantation;
  3. Patients who are not suitable or unwilling to undergo traditional allogeneic hematopoietic stem cell transplantation;
  4. creatinine clearance > 60ml/min; without liver invasion, serum total bilirubin ≤ 1.5 times the upper limit of normal, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were both ≤ 3 times the upper limit of the normal range. If there is liver invasion, serum erythrambirubin ≤ 3 times the upper limit of normal, and serum ALT and AST are both ≤ 5 times the upper limit of the normal range;
  5. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
  6. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;
  7. Estimated survival time ≥ 3 months;
  8. ECOG performance status 0 to 1;
  9. Females and males of childbearing potential must agree to use adequate contraception prior to study entry, during study participation, and for 6 months after infusion (the safety of this therapy for unborn children is not known and has unknown risks);
  10. Those who voluntarily participated in this trial and provided informed consent;

排除标准:Exclusion Criteria:

  1. Allergy to pre-treatment measures;
  2. Those with acute graft versus host disease (GvHD) or moderate to severe chronic GvHD within 4 weeks before screening; Those who have received systemic drug therapy for GvHD within 4 weeks before the reinfusion;
  3. History of epilepsy or other central nervous system disorders;
  4. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
  5. Less than 100 days after allogeneic hematopoietic stem cell transplantation;
  6. Patients with HIV infection,Active infection of hepatitis B virus or hepatitis C virus,Uncured active infection;
  7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
  8. Received anti-cancer chemotherapy or other drug treatment within 2 weeks prior to screening;
  9. Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the results of the study.

引自 ClinicalTrials.gov, NCT06633328, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06633328,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06633328